Informational:Informational:Custom mRNA Synthesis Services are now available to streamline your mRNA workflow. Learn more »
Invitrogen™

mMESSAGE mMACHINE™ T7 mRNA Kit with CleanCap™ Reagent AG

Catalog number: A57620
Invitrogen™

mMESSAGE mMACHINE™ T7 mRNA Kit with CleanCap™ Reagent AG

Catalog number: A57620
Catalog Number
A57620
Unit Size
50 reactions
Price (USD)
Availability
-
Quantity
Catalog Number
Unit Size
1000 reactions
Price (USD)
Availability
-
Quantity
Catalog NumberUnit SizePrice (USD)AvailabilityQuantity
A5762050 reactions
-
A576211000 reactions
-
Product Overview
Figures
Videos
Recommendations
Recommendations
Documents
FAQ
Citations & References
Additional Information
Recommendations

The mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG contains all the reagents and buffers necessary for in vitro synthesis of large amounts of mRNA with the naturally occurring Cap 1 structure for increased translatability in vivo compared to legacy capping methods such as the use of anti-reverse capping analog (ARCA). Each standard 20-μL reaction yields a minimum of 100 μg of Cap 1-containing mRNA, while the scaled-up protocol yields up to 1 mg of mRNA. This kit is suitable for full- or partially-modified-nucleotide substitution to generate modified mRNA.

Features of the mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG include:
• Contains proven CleanCap capping technology
• Optimized to achieve high mRNA yields (>5 mg/mL)
• Produces mRNA that is over 90% capped
• Allows use of modified nucleotides
• Includes GFP control template
• Made up of high quality reagents (TheraPure)
• Available in two sizes: 50 and 1000 reactions

The mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG contains the trinucleotide cap analog CleanCap Reagent AG, which has the Cap 1 structure and can be used for co-transcriptional capping of mRNA without compromising yield. This reagent produces high capping efficiencies compared to legacy capping reagents such as ARCA. Cap 1-containing mRNAs can have superior translational activities compared to Cap 0 mRNAs produced using ARCA or mCap cap analogs.

A linearized DNA template containing an AG-initiating T7 RNA polymerase promoter is strongly recommended for this kit to achieve mRNA yields >5 mg/mL with over 90% of the transcripts capped. The mRNA produced with this kit can be used for many applications, including transfections, preclinical mRNA therapeutic mRNA studies, microinjections, in vitro translation, and RNA structure and function analysis.

For Research Use Only.

Specifications

Cell Type
HEK293, 293, HeLa, CHO-K1, CHO, Jurkat, Primary Human T Cells, Primary Cells, Stem Cells, iPSC, NIH-3T3, HepG2, A549, HUVEC
Final Product Type
Synthetic mRNA, mRNA
Format
Kit
Isolation Technology
Silica Spin Column
Purification Target
mRNA, Synthetic mRNA
Sample Type
mRNA, Synthetic mRNA
No. of Reactions
50 Reactions

Figures

Documents & Downloads

Certificates

    Frequently asked questions (FAQs)

    Citations & References

    Search citations by name, author, journal title or abstract text